Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jul;68(1):181–185. doi: 10.1038/bjc.1993.310

Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?

A R Dixon 1, L Jackson 1, S Y Chan 1, R A Badley 1, R W Blamey 1
PMCID: PMC1968296  PMID: 8318411

Abstract

A biochemical response index comprising ESR, CEA and CA 15.3 was evaluated in 67 patients with systemic breast cancer treated by chemotherapy; 55 were assessable by UICC criteria and the response index (96% of all UICC assessable patients). Marker changes at 2 and 4 months showed a highly significant correlation with the UICC assessed response at 3 and 6 months (P < 0.001); sensitivity 100%, specificity 87%; positive predictive value 85%; negative predictive value 100%. This index was then used to select out truly responsive patients and to prospectively direct their chemotherapy. Twenty-six responding (biochemical/clinical) patients were randomised to discontinue cytotoxics after 6 months and move to maintenance hormones (n = 13) or continue chemotherapy whilst the biochemical markers kept falling or remained within the normal range. Biochemical progression prompted a change of chemotherapy. Continuous chemotherapy in biochemically defined responders was associated with a significant lengthening of remission duration and an improved quality of life and survival. We are now using the index to routinely direct chemotherapy and select out true responders for maintenance chemotherapy.

Full text

PDF
181

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Coates A., Gebski V., Bishop J. F., Jeal P. N., Woods R. L., Snyder R., Tattersall M. H., Byrne M., Harvey V., Gill G. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med. 1987 Dec 10;317(24):1490–1495. doi: 10.1056/NEJM198712103172402. [DOI] [PubMed] [Google Scholar]
  2. Coombes R. C., Powles T. J., Gazet J. C., Ford H. T., Sloane J. P., Laurence D. J., Neville A. M. Biochemical markers in human breast cancer. Lancet. 1977 Jan 15;1(8003):132–134. doi: 10.1016/s0140-6736(77)91719-6. [DOI] [PubMed] [Google Scholar]
  3. Cove D. H., Woods K. L., Smith S. C., Burnett D., Leonard J., Grieve R. J., Howell A. Tumour markers in breast cancer. Br J Cancer. 1979 Nov;40(5):710–718. doi: 10.1038/bjc.1979.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cowen D. M., Searle F., Ward A. M., Benson E. A., Smiddy F. G., Eaves G., Cooper E. H. Multivariate biochemical indicators of breast cancer: an evaluation of their potential in routine practice. Eur J Cancer. 1978 Aug;14(8):885–893. doi: 10.1016/0014-2964(78)90105-6. [DOI] [PubMed] [Google Scholar]
  5. Franchimont P., Zangerle P. F., Nogarede J., Bury J., Molter F., Reuter A., Hendrick J. C., Collette J. Simultaneous assays of cancer-associated antigens in various neoplastic disorders. Cancer. 1976 Dec;38(6):2287–2295. doi: 10.1002/1097-0142(197612)38:6<2287::aid-cncr2820380616>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  6. Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  7. Hortobagyi G. N., Blumenschein G. R., Buzdar A. U., Yap H. Y., Schell F. C., Barnes B. C., Burgess M. A. Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy. J Surg Oncol. 1981;18(2):163–172. doi: 10.1002/jso.2930180210. [DOI] [PubMed] [Google Scholar]
  8. Lee E. T., Desu M. M. A computer program for comparing K samples with right-censored data. Comput Programs Biomed. 1972 Nov;2(4):315–321. doi: 10.1016/0010-468x(72)90019-0. [DOI] [PubMed] [Google Scholar]
  9. Patel J. K., Nemoto T., Vezeridis M., Petrelli N., Suh O., Dao T. L. Does more intense palliative treatment improve overall survival in metastatic breast cancer patients? Cancer. 1986 Feb 1;57(3):567–570. doi: 10.1002/1097-0142(19860201)57:3<567::aid-cncr2820570328>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  10. Powles T. J., Coombes R. C., Smith I. E., Jones J. M., Ford H. T., Gazet J. C. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet. 1980 Mar 15;1(8168 Pt 1):580–582. doi: 10.1016/s0140-6736(80)91066-1. [DOI] [PubMed] [Google Scholar]
  11. Smalley R. V., Murphy S., Huguley C. M., Jr, Bartolucci A. A. Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Res. 1976 Nov;36(11 Pt 1):3911–3916. [PubMed] [Google Scholar]
  12. Tannock I. F., Boyd N. F., DeBoer G., Erlichman C., Fine S., Larocque G., Mayers C., Perrault D., Sutherland H. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988 Sep;6(9):1377–1387. doi: 10.1200/JCO.1988.6.9.1377. [DOI] [PubMed] [Google Scholar]
  13. Williams M. R., Turkes A., Pearson D., Griffiths K., Blamey R. W. An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. Br J Cancer. 1990 Jan;61(1):126–132. doi: 10.1038/bjc.1990.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. de Haes J. C., van Knippenberg F. C., Neijt J. P. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 1990 Dec;62(6):1034–1038. doi: 10.1038/bjc.1990.434. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES